CAS: 32909-92-5; Sulfametrole

上下游产品

CAS号5728-16-5 3-氯-4-甲氧基-1,2,5-噻二唑 | CAS号63-74-1 磺胺

📜3-氯-4-甲氧基-1,2,5-噻二唑,磺胺置于potassium Carbonate体系中,用 二甲基亚砜 作为反应溶剂,以96.82%的收率获得产物磺胺美曲
参考文献:Process For Preparing
标题:Process For Preparing
摘要:3-甲氧基-4-(4'-氨基苯磺酰胺基)-1,2,5-噻二唑是通过在二甲基亚砜作作为反应溶剂和碱性氢氧化物或碳酸盐的存在下,将3-甲氧基-4-氯-1,2,5-噻二唑与磺胺甲苯反应制备而成,反应温度为室温至95°C,每摩尔噻二唑化合物使用1.2至1.5摩尔磺胺甲苯和1.5至3摩尔碱性氢氧化物或碳酸盐,然后通过酸化得到反应产物.

专利信息

专利号:US-9295731-B2
优先权日:2013-04-01
标题 :Cleavable drug conjugates, compositions thereof and methods of use
发明人：NGUYEN MARK QUANG
权利人:NGUYEN MARK QUANG
摘要:Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.

专利号:US-2023398101-A1
优先权日:2022-06-09
标题 :Co-agents as Therapy Against Anaerobic Pathogens
发明人：PACE JOHN LEE; HARTSELL THERESA LYNN
权利人:FLEURIR ABX LLC
摘要:Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment. Some co-agent combinations and/or formulations contain one or more existing antibiotic agents being repurposed for utility against difficult to treat anaerobic pathogens.